Tech Company Financing Transactions
Tallac Therapeutics Funding Round
Tallac Therapeutics closed a $62 million Series A venture capital round on 12/2/2020. Investors included Lightstone Ventures, Matrix Partners and Morningside Group.
Transaction Overview
Company Name
Announced On
12/2/2020
Transaction Type
Venture Equity
Amount
$62,000,000
Round
Series A
Investors
Proceeds Purpose
The Company plans to use the Series A funding to advance the discovery and development of immunotherapy candidates for multiple solid tumor maligniancies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
866 Malcolm Rd. 100
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Website
Email Address
Overview
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Several TRAAC molecules are in various stages of discovery and preclinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hong Wan
VP - Bus. Development
Janet Sim
VP - Finance
Emma Abellana
Browse more venture capital transactions:
Prev: 12/2/2020: Infogrid venture capital transaction
Next: 12/2/2020: Newomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs